Description of the medicine: Doxorubicin hydrochloride (Doxorubicini hydrochloridum)
DOXORUBICINE HYDROCHLORIDE (Doxorubicini hydrochloridum).
Antitumor antibiotic anthracycline series. The chemical structure is close to rubomycin (see). It differs only in that in position 14 it contains, instead of the acetyl group, COSH3 an oxyacetyl COCH 2 OH, i.e. may be considered as oxyrubomycin.
Synonyms: Adriablastin, Adriamycin, Axidoxo, Blastocin, Doxolem, Doxorubifer, Rastocin, Adriamicin, Adriblastin, Aksidoxo, Doxolem, Doxorubicin, Doxorubiferum, Farmiblastina, Hydroxydaunomycin, Rastocin.
Red crystalline powder or porous mass. It is sparingly soluble in water, insoluble in alcohol.
Doxorubicin has a high antitumor and anti-leukemia activity. According to the mechanism of action, it is close to rubomycin and has the ability to intercalate the DNA of cells. It has a depressing effect on blood formation. It has immunosuppressive activity.
Doxorubicin is used for breast cancer, soft tissue sarcoma, osteogenic sarcoma, Ewing's tumor, lung cancer, lymphosarcoma, ovarian cancer, squamous cell carcinoma of various localization, bladder cancer, Wilms tumor, thyroid cancer, acute leukemia, lymphogranulomatosis.
Enter only intravenously. Assign according to one of the following schemes: a) 30 mg per 1 m 2 of body surface daily for 3 days; intervals between courses are 4 weeks; b) 60 mg / m 2 once every 3 weeks; c) for ZOMg / m 2 once a week (1st, 8th and 15th days of the course). Courses are repeated at intervals of 3 weeks.
The total dose of doxorubicin should not exceed 550 mg / m 2.
In patients who previously received radiation therapy to the area of the lungs and mediastinum, the total dose of doxorubicin should not exceed 400 mg / m 2.
For intravenous administration, the contents of the doxorubicin vial (10 mg) are dissolved in 5 ml of isotonic sodium chloride solution.
With the use of doxorubicin, leukopenia and thrombocytopenia, stomatitis, nausea and vomiting (immediately after administration of the drug), alopecia (reversible), allergic reactions, necrosis of subcutaneous fatty tissue when the drug enters the skin, phlebitis are possible.
The use of doxorubicin must be carried out under strict hematological control.
One of the characteristic toxicological features of doxorubicin is its cardiotoxic effect.
In the process of treatment with the drug, cardiomyopathy, pain in the heart, rhythm disturbances, heart failure, decreased blood pressure may develop. In severe heart rhythm disturbances or congestive failure, doxorubicin treatment should be stopped immediately.
The use of doxorubicin is contraindicated in severe violations of the liver and kidneys, leukopenia (below 3, 5 x 10 9 / l), thrombocytopenia (below 12 x 10 9 / l), severe concomitant heart diseases (myocarditis, myocardial infarction, significant rhythm disturbances), bleeding , tuberculosis, pregnancy, peptic ulcer and duodenal ulcer.